VivaVision Biotech
PrivateLast Round
Series D+
Nov 1, 2025
Est. Valuation
$257.37M
Total Funding Raised
$131.09M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
VivaVision Biotech is a clinical-stage pharmaceutical company that develops best-in-class and first-in-class therapies for ocular diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VivaVision Biotech Comparables
Compare VivaVision Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BRIM Biotechnology, Inc. | 81% | |
| Arctic Vision | 80% | |
| Ocumension Therapeutics | 80% | |
VivaVision Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D+ | Nov 1, 2025 | ||||
| Grant | Jan 5, 2024 | ||||
| Series D Extension | May 6, 2023 | ||||
| Series D Extension | Apr 1, 2023 | ||||
| Series D | Apr 19, 2021 | ||||
Series C | Nov 1, 2019 |
VivaVision Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| V-Capital | Series D Extension |
| Lapam Capital | Series D, Series B |
| Cenova Capital | Series D |
| Viva Biotech | Series B, Series A Extension, Series D |
| Innovation and Technology Commission | Grant |
| JMCR Partners | Series D, Series C |
| Shenzhen GTJA Investment Group | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 3, 2026
Monthly visitors increased 54% MoM.
- Nov 1, 2025
$25M raised in Series D+ round.
VivaVision Biotech Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about VivaVision Biotech's valuation, stock price, and market status.